Literature DB >> 30238266

The 88-item Multiple Sclerosis Spasticity Scale: a Rasch validation of the Italian version and suggestions for refinement of the original scale.

Leonardo Pellicciari1, Marcella Ottonello2, Andrea Giordano3, Caterina Albensi4, Franco Franchignoni5.   

Abstract

BACKGROUND: In multiple sclerosis (MS), the impact of spasticity on the patient's life is a key issue, and it is fundamental that existing tools measuring the patient's perspective undergo psychometric analysis and refinement to optimize confidence in their use in clinical practice and research.
OBJECTIVE: We examined-by Rasch analysis (RA)-the main metric characteristics of the 88-item Multiple Sclerosis Spasticity Scale (MSSS-88) to: (i) further validate its Italian version (MSSS-88-IT), previously validated through classical test theory methods only and (ii) independently verify the measurement properties of the original scale.
METHODS: MSSS-88 data from a convenience sample of 232 subjects with MS underwent RA, mainly examining item fit, reliability indices, test information function, dimensionality, local item independence, and differential item functioning (DIF).
RESULTS: Most items fitted the Rasch model, but 13/88 items showed a misfit in infit and/or outfit values. Rasch reliability indices were high (> 0.80). Test information functions in most subscales showed a sharp decrease in measurement precision as the ability level departs from the quite limited central range of maximal information. The unidimensionality of each subscale was confirmed. Thirteen item pairs showed local dependency (residual correlations > 0.30) and three items presented DIF.
CONCLUSION: Reliability, dimensionality and some internal construct validity characteristics of the MSSS-88-IT were confirmed. But, drawbacks of the original MSSS-88 emerged related to some item misfit, redundancy, or malfunctioning. Thus, further large independent studies are recommended, to verify the robustness of previous findings and examine the appropriateness of a few targeted item replacements.

Entities:  

Keywords:  Multiple sclerosis; Patient-reported outcome measure; Psychometrics; Rasch model; Spasticity

Mesh:

Year:  2018        PMID: 30238266     DOI: 10.1007/s11136-018-2005-2

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  23 in total

Review 1.  Guidelines for the process of cross-cultural adaptation of self-report measures.

Authors:  D E Beaton; C Bombardier; F Guillemin; M B Ferraz
Journal:  Spine (Phila Pa 1976)       Date:  2000-12-15       Impact factor: 3.468

2.  Transcranial magnetic stimulation primes the effects of exercise therapy in multiple sclerosis.

Authors:  Francesco Mori; Concetta Ljoka; Elisabetta Magni; Claudia Codecà; Hajime Kusayanagi; Fabrizia Monteleone; Andrea Sancesario; Giorgio Bernardi; Giacomo Koch; Calogero Foti; Diego Centonze
Journal:  J Neurol       Date:  2011-02-01       Impact factor: 4.849

Review 3.  Spasticity management in multiple sclerosis.

Authors:  Christina Hughes; Ileana M Howard
Journal:  Phys Med Rehabil Clin N Am       Date:  2013-11       Impact factor: 1.784

4.  A Cross-Sectional Study of the Impact of Spasticity on Daily Activities in Multiple Sclerosis.

Authors:  Francois Bethoux; Ruth Ann Marrie
Journal:  Patient       Date:  2016-12       Impact factor: 3.883

5.  A randomized trial of memantine as treatment for spasticity in multiple sclerosis.

Authors:  Lahar R Mehta; Michael P McDermott; Andrew D Goodman; Steven R Schwid
Journal:  Mult Scler       Date:  2009-12-22       Impact factor: 6.312

6.  Spasticity in multiple sclerosis: Associations with impairments and overall quality of life.

Authors:  K Milinis; A Tennant; C A Young
Journal:  Mult Scler Relat Disord       Date:  2015-10-22       Impact factor: 4.339

7.  The cross-cultural adaptation and psychometric validation of the MSSS-88 for use in Italian patients with multiple sclerosis.

Authors:  Marcella Ottonello; Leonardo Pellicciari; Diego Centonze; Calogero Foti; Caterina Pistarini; Caterina Albensi; Andrea Giordano
Journal:  Disabil Rehabil       Date:  2017-10-25       Impact factor: 3.033

8.  The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.

Authors:  Susan Ball; Jane Vickery; Jeremy Hobart; Dave Wright; Colin Green; James Shearer; Andrew Nunn; Mayam Gomez Cano; David MacManus; David Miller; Shahrukh Mallik; John Zajicek
Journal:  Health Technol Assess       Date:  2015-02       Impact factor: 4.014

9.  Prevalence and treatment of spasticity reported by multiple sclerosis patients.

Authors:  M A Rizzo; O C Hadjimichael; J Preiningerova; T L Vollmer
Journal:  Mult Scler       Date:  2004-10       Impact factor: 6.312

10.  Linguistic and psychometric validation of the MSSS-88 questionnaire for patients with multiple sclerosis and spasticity in Germany.

Authors:  Thomas Henze; Sylvia von Mackensen; Gerald Lehrieder; Uwe K Zettl; Carmen Pfiffner; Peter Flachenecker
Journal:  Health Qual Life Outcomes       Date:  2014-08-01       Impact factor: 3.186

View more
  1 in total

1.  Intensive Neurorehabilitation and Gait Improvement in Progressive Multiple Sclerosis: Clinical, Kinematic and Electromyographic Analysis.

Authors:  Su-Chun Huang; Simone Guerrieri; Gloria Dalla Costa; Marco Pisa; Giulia Leccabue; Lorenzo Gregoris; Giancarlo Comi; Letizia Leocani
Journal:  Brain Sci       Date:  2022-02-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.